DR. MICHAEL H VEEDER MD NPI 1568463305

NPI Details

DR. Michael H Veeder, MD is a hematology and oncology internal medicine in Peoria, IL with 55 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Michael H Veeder, MD NPI is 1568463305. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: YALE UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1971

The provider's business location address is:

8940 N WOOD SAGE RD
PEORIA, IL
ZIP 61615-822
Phone: (309) 243-3000
Fax: (309) 243-3050

The NPI 1568463305 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Protein measurement, serum (HCPCS:84165)
• Iron level (HCPCS:83540)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron binding capacity (HCPCS:83550)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection of drug or substance into vein (HCPCS:96374)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Ct scan of chest with contrast (HCPCS:71260)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Folic acid level, serum (HCPCS:82746)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Dxa bone density measurement of hip, pelvis, spine (HCPCS:77080)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Red blood count, automated test (HCPCS:85045)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)

The enumeration date for this NPI number is 8/2/2005 and was last updated on 4/9/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: